Ribo Life-B (RIBOLIFE-B) (ASX: 06938) shares rose more than 5% in morning trading, up 4.88% as of press time to HK$53.65, with a turnover of HK$3.5805 million.

Recently, according to the company's official WeChat account, Ribo Life announced that its wholly-owned subsidiary Ribotaike (Shandong) Biomedical Technology Co., Ltd. ("Ribotaike") has officially completed its automated intelligent drug screening center. The center relies on automated robot clusters and an intelligent data analysis foundation to build a standardized technology platform suitable for early-stage small nucleic acid drug discovery and preclinical research, marking a key leap in the company's small nucleic acid drug R&D in automation, digitization, and intelligent construction.

Ribo Life is entering a phase of accelerated pipeline achievement: its self-developed liver-targeting technology continues to mature, and extrahepatic delivery technology has achieved important breakthroughs. Currently, the company has 7 clinical-stage assets, more than 20 preclinical assets, and over 45 early-stage R&D projects, with a pipeline covering major unmet clinical needs in cardiovascular, metabolic, kidney, and liver disease areas.

The completion of this automated intelligent screening center will further amplify the collaborative value of AI plus automation, continuously improve the efficiency and predictability of small nucleic acid drug R&D, accelerate the entire chain from target discovery and molecule design to clinical advancement, and drive the accelerated translation of siRNA source innovation achievements into clinical applications.